85.13 0.00 (0.00%)
After hours: 4:30PM EDT
|Bid||82.21 x 100|
|Ask||85.60 x 400|
|Day's Range||82.74 - 87.24|
|52 Week Range||39.21 - 92.98|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 7, 2018 - May 11, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||104.83|
SAN DIEGO , March 7, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that Kevin Gorman , CEO of Neurocrine Biosciences, will present at the following investor conferences: ...
AbbVie Inc. and Neurocrine Biosciences Inc. shares rose 1.7% and 1.1% respectively in premarket trade Wednesday after the companies announced that their drug met its primary endpoint in a phase 3 trial ...
− First of two pivotal Phase 3 studies met primary efficacy endpoint and all ranked secondary endpoints − Results demonstrated elagolix, in combination with low-dose add-back therapy, reduced heavy menstrual ...
On Feb. 14, 2018, Neurocrine Biosciences, Inc. (NBIX) announced the company will file a new drug application (NDA) for opicapone in the first half of 2019 following receipt of the meeting minutes from the January 2018 meeting with the FDA. During that meeting, the FDA did not request that Neurocrine conduct an additional Phase 3 study for opicapone prior to filing the NDA. Opicapone is a peripherally-acting and highly selective inhibitor of catechol-o-methyltransferase (COMT) to be used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors in patients with Parkinson’s disease (PD).
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
SAN DIEGO, Feb. 14, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX), a biotechnology company focused on neurological and endocrine related disorders, today announced that the U.S. Food and Drug Administration (FDA) has provided guidance on the regulatory path forward to support the New Drug Application (NDA) for opicapone, an investigational drug for Parkinson's disease, after receiving meeting minutes from the January 2018 meeting with the FDA. Most importantly, the Neurology Division of the FDA has not requested that Neurocrine conduct an additional Phase III study for opicapone prior to the NDA filing.
The San Diego-based company said it had profit of 7 cents per share. The results missed Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for earnings ...
INGREZZA® (valbenazine) Fourth Quarter Net Product Sales of $64.5 Million with Approximately 9,100 TRx INGREZZA Net Product Sales of $116.6 Million with Approximately 14,900 TRx Since Commercial Launch ...
NEW YORK, NY / ACCESSWIRE / February 13, 2018 / Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 13, 2018, at 5:00 ...
Live Audio Webcast Will be on February 15, 2018 SAN DIEGO , Feb. 8, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the Leerink Partners 7 th Annual Global Healthcare Conference ...
CEO of Neurocrine Biosciences Inc (NASDAQ:NBIX) Kevin Charles Gorman sold 105,983 shares of NBIX on 02/06/2018 at an average price of $80.25 a share.
Conference Call and Webcast Scheduled for Tuesday, February 13 SAN DIEGO , Feb. 6, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it will report fourth quarter and ...
Cara Therapeutics’ (CARA) investigational drug candidate, CR845, is being developed for providing pain relief. Intravenous (or IV) CR845 has shown a pain relief and tolerability profile in three Phase 2 clinical trials in patients with acute postoperative pain. Cara Therapeutics has initiated a Phase 3 clinical trial program for IV CR845 for postoperative pain in patients undergoing a range of abdominal surgeries.
Cara Therapeutics (CARA) is a clinical-stage biopharmaceutical company focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by targeting peripheral kappa opioid receptors in affected patients. The company is developing a novel class of product candidates that target the body’s peripheral nervous system and certain immune cells. Of the seven analysts covering Cara Therapeutics in January 2018, six analysts gave the stock a “buy” or higher rating, and one recommended “hold.” The stock has a mean rating of 1.9 and a target price of $24.29.
NEW YORK, Jan. 23, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Leidos ...
On October 27, 2017, AbbVie (ABBV) announced that the New Drug Application (or NDA) for its investigational drug Elagolix, which is used for managing endometriosis-related pain, had been granted priority review by the FDA. AbbVie has developed Elagolix in collaboration with Neurocrine Biosciences (NBIX). AbbVie expects this oral gonadotropin-releasing hormone (or GnRH) antagonist to be approved by its Prescription Drug User Fee Act (or PDUFA) date in 2Q18.